Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 10/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 5/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15449639 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CHRNA7MLNRCYP2D6PTGDR | |
| SCHEMBL25365925 | 0.83 | ALDH1A1 (0.67) | ALDH1A1CHRNA7KDM4EMLNRCYP2D6 | |
| SCHEMBL307288 | 0.83 | ALDH1A1 (0.67) | ALDH1A1CHRNA7KDM4EMLNRCYP2D6 | |
| SCHEMBL29995133 | 0.83 | ALDH1A1 (0.67) | ALDH1A1CHRNA7KDM4EMLNRCYP2D6 | |
| Hydrochloric Acid SCHEMBL28296115 | 0.81 | KDM4E (0.47) | ALDH1A1CHRNA7KDM4EMLNRCYP2D6 | |
| SCHEMBL2120289 | 0.80 | KDM4E (0.53) | ALDH1A1KDM4ENAPRT | |
| Hydrochloric Acid SCHEMBL28016002 | 0.79 | KDM4E (0.52) | ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL27866010 | 0.79 | KDM4E (0.52) | ALDH1A1KDM4E | |
| SCHEMBL11154024 | 0.72 | KMT2A (0.52) | ALDH1A1 | |
| SCHEMBL370097 | 0.72 | ALDH1A1 (0.49) | ALDH1A1CHRNA7ACACBACACAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | claimed |
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | claimed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | claimed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | claimed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1507756-A4 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | claimed |
| JP-2005526857-A | — | — | 2005-09-08 | — | — | JP | claimed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| EP-1507756-B1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9035096-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-1507756-A4 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050137179-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2005-06-23 | — | — | US | disclosed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | ALDH1A1 2607/4885CHRNA7 833/4885KDM4E 3799/4885 |
| US-20050137179-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | ALDH1A1 2054/4885CHRNA7 3769/4885KDM4E 4803/4885 |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | ALDH1A1 2607/4885CHRNA7 833/4885KDM4E 3799/4885 |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | ALDH1A1 2607/4885CHRNA7 833/4885KDM4E 3799/4885 |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | ALDH1A1 2607/4885CHRNA7 833/4885KDM4E 3799/4885 |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | ALDH1A1 2607/4885CHRNA7 833/4885KDM4E 3799/4885 |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | ALDH1A1 2054/4885CHRNA7 3769/4885KDM4E 4803/4885 |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | ALDH1A1 2607/4885CHRNA7 833/4885KDM4E 3799/4885 |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | ALDH1A1 2607/4885CHRNA7 833/4885KDM4E 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.